Products Extended-release Onapristone + Anastrozole
Extended-release Onapristone + Anastrozole Phase 2 Active ⚡ Active Refractory Endometrial Adenocarcinoma
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma
Jan 28, 2021 → Dec 31, 2025
About Extended-release Onapristone + Anastrozole Extended-release Onapristone + Anastrozole is a phase 2 stage product being developed by Context Therapeutics for Refractory Endometrial Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04719273. Target conditions include Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT04719273 Phase 2 Active Jan 28, 2021 Dec 31, 2025 Refractory Endometrial Adenocarcinoma
Competing Products 20 competing products in Refractory Endometrial Adenocarcinoma
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 perampanel Eisai Phase 2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3
Other Products from Context Therapeutics